Table 1.
Baseline characteristics of men and women with colorectal cancer aged 15-99 years in the QResearch derivation cohort and QResearch and Public Health England (PHE) validation cohorts based on information recorded in the cancer registry. Values are numbers (percentages) unless stated otherwise
| Characteristics | Women | Men | |||||
|---|---|---|---|---|---|---|---|
| QResearch derivation cohort | QResearch validation cohort | PHE validation cohort | QResearch derivation cohort | QResearch validation cohort | PHE validation cohort | ||
| Total No of patients | 19 708 | 6800 | 196 239 | 24 437 | 8414 | 241 582 | |
| Mean (SD) age at diagnosis (years) | 72.5 (12.8) | 72.7 (12.8) | 72.5 (12.9) | 70.9 (11.5) | 70.9 (11.6) | 70.5 (11.7) | |
| Age group (years): | |||||||
| 15-19 | 17 (0.1) | 4 (0.1) | 181 (0.1) | 6 (0.0) | 3 (0.0) | 119 (0.0) | |
| 20-29 | 67 (0.3) | 33 (0.5) | 817 (0.4) | 65 (0.3) | 16 (0.2) | 775 (0.3) | |
| 30-39 | 241 (1.2) | 68 (1.0) | 2201 (1.1) | 215 (0.9) | 93 (1.1) | 2420 (1.0) | |
| 40-49 | 729 (3.7) | 251 (3.7) | 7279 (3.7) | 807 (3.3) | 266 (3.2) | 8113 (3.4) | |
| 50-59 | 1960 (9.9) | 650 (9.6) | 20 146 (10.3) | 2679 (11.0) | 931 (11.1) | 27 545 (11.4) | |
| 60-69 | 4097 (20.8) | 1408 (20.7) | 40 588 (20.7) | 6376 (26.1) | 2197 (26.1) | 64 424 (26.7) | |
| 70-79 | 6069 (30.8) | 2084 (30.6) | 59 928 (30.5) | 8356 (34.2) | 2854 (33.9) | 82 423 (34.1) | |
| 80-89 | 5371 (27.3) | 1896 (27.9) | 53 492 (27.3) | 5257 (21.5) | 1817 (21.6) | 49 535 (20.5) | |
| 90-99 | 1157 (5.9) | 406 (6.0) | 11 607 (5.9) | 676 (2.8) | 237 (2.8) | 6228 (2.6) | |
| Ethnicity: | |||||||
| Recorded | 17005 (86.3) | 5896 (86.7) | 144409 (73.6) | 21539 (88.1) | 7435 (88.4) | 184127 (76.2) | |
| White or not recorded | 19150 (97.2) | 6603 (97.1) | 191 802 (97.7) | 23 699 (97.0) | 8183 (97.3) | 235 692 (97.6) | |
| Indian | 84 (0.4) | 28 (0.4) | 756 (0.4) | 147 (0.6) | 40 (0.5) | 1184 (0.5) | |
| Pakistani | 32 (0.2) | 14 (0.2) | 373 (0.2) | 57 (0.2) | 10 (0.1) | 495 (0.2) | |
| Bangladeshi | 40 (0.2) | 12 (0.2) | 139 (0.1) | 48 (0.2) | 14 (0.2) | 166 (0.1) | |
| Other Asian | 53 (0.3) | 14 (0.2) | 297 (0.2) | 60 (0.2) | 18 (0.2) | 404 (0.2) | |
| Black Caribbean | 123 (0.6) | 54 (0.8) | 900 (0.5) | 168 (0.7) | 61 (0.7) | 1097 (0.5) | |
| Black African | 49 (0.2) | 18 (0.3) | 386 (0.2) | 67 (0.3) | 22 (0.3) | 429 (0.2) | |
| Chinese | 27 (0.1) | 13 (0.2) | 302 (0.2) | 34 (0.1) | 17 (0.2) | 377 (0.2) | |
| Other | 150 (0.8) | 44 (0.6) | 1284 (0.7) | 157 (0.6) | 49 (0.6) | 1738 (0.7) | |
| Year of diagnosis: | |||||||
| 1998-2005 | 7462 (37.9) | 2625 (38.6) | 87 301 (44.5) | 8786 (36.0) | 3174 (37.7) | 104 651 (43.3) | |
| 2006-14 | 12 246 (62.1) | 4175 (61.4) | 108 938 (55.5) | 15 651 (64.0) | 5240 (62.3) | 136 931 (56.7) | |
| Type of cancer: | |||||||
| Colon | 13 641 (69.2) | 4580 (67.4) | 134 832 (68.7) | 14 579 (59.7) | 5078 (60.4) | 143 254 (59.3) | |
| Rectal | 4735 (24.0) | 1710 (25.1) | 47 966 (24.4) | 7939 (32.5) | 2694 (32.0) | 78 821 (32.6) | |
| Rectosigmoid | 1332 (6.8) | 510 (7.5) | 13 441 (6.8) | 1919 (7.9) | 642 (7.6) | 19 507 (8.1) | |
| Townsend deprivation fifth: | |||||||
| 1 (most affluent) | 4505 (22.9) | 1594 (23.4) | 37 911 (19.3) | 5649 (23.1) | 2076 (24.7) | 48 605 (20.1) | |
| 2 | 4612 (23.4) | 1460 (21.5) | 42 934 (21.9) | 5775 (23.6) | 1788 (21.3) | 52 517 (21.7) | |
| 3 | 3968 (20.1) | 1419 (20.9) | 43 032 (21.9) | 4837 (19.8) | 1636 (19.4) | 51 619 (21.4) | |
| 4 | 3559 (18.1) | 1275 (18.8) | 39 510 (20.1) | 4236 (17.3) | 1484 (17.6) | 47 309 (19.6) | |
| 5 (most deprived) | 3064 (15.5) | 1052 (15.5) | 32 852 (16.7) | 3940 (16.1) | 1430 (17.0) | 41 532 (17.2) | |
| Cancer stage at diagnosis: | |||||||
| Stage recorded | 14 193 (72.0) | 4724 (69.5) | 140 613 (71.7) | 18 044 (73.8) | 5918 (70.3) | 177 401 (73.4) | |
| 1 | 2030 (10.3) | 697 (10.3) | 19 542 (10.0) | 2763 (11.3) | 938 (11.1) | 26 977 (11.2) | |
| 2 | 4926 (25.0) | 1592 (23.4) | 47 791 (24.4) | 5783 (23.7) | 1942 (23.1) | 57 679 (23.9) | |
| 3 | 4715 (23.9) | 1645 (24.2) | 48 194 (24.6) | 6205 (25.4) | 2052 (24.4) | 60 040 (24.9) | |
| 4 | 2522 (12.8) | 790 (11.6) | 25 086 (12.8) | 3293 (13.5) | 986 (11.7) | 32 705 (13.5) | |
| Cancer grade at diagnosis: | |||||||
| Grade recorded | 15 077 (76.5) | 5066 (74.5) | 147 796 (75.3) | 19 293 (78.9) | 6508 (77.3) | 189 146 (78.3) | |
| Well differentiated | 1110 (5.6) | 366 (5.4) | 10 499 (5.4) | 1306 (5.3) | 479 (5.7) | 13 168 (5.5) | |
| Moderately differentiated | 11 162 (56.6) | 3787 (55.7) | 109 278 (55.7) | 15 003 (61.4) | 5122 (60.9) | 147 237 (60.9) | |
| Poorly differentiated | 2777 (14.1) | 900 (13.2) | 27 589 (14.1) | 2949 (12.1) | 893 (10.6) | 28 332 (11.7) | |
| Undifferentiated | 28 (0.1) | 13 (0.2) | 430 (0.2) | 35 (0.1) | 14 (0.2) | 409 (0.2) | |
| Treatment within 12 months of diagnosis: | |||||||
| Surgery | 14 729 (74.7) | 4971 (73.1) | 145 376 (74.1) | 18 539 (75.9) | 6276 (74.6) | 182 573 (75.6) | |
| Chemotherapy | 5504 (27.9) | 1849 (27.2) | 52 228 (26.6) | 8063 (33.0) | 2665 (31.7) | 76 495 (31.7) | |
| Radiotherapy | 2325 (11.8) | 870 (12.8) | 22 255 (11.3) | 4116 (16.8) | 1361 (16.2) | 39 175 (16.2) | |